Ellume: 91%+ accurate at-home COVID test given first emergency authorization in the US

Credit: Ellume
Credit: Ellume

The Food and Drug Administration on [December 15] issued an emergency authorization for the country’s first coronavirus test that can run from start to finish at home without the need for a prescription.

People as young as 2 years old are cleared to use the test, which takes just 15 to 20 minutes to deliver a result. Unlike many similar products, which are only supposed to be used by people with symptoms of Covid-19, this test is authorized for people with or without symptoms.

The test, developed by the Australian company Ellume, detects bits of coronavirus proteins called antigens. It’s slightly less accurate than gold standard laboratory tests designed to look for coronavirus genetic material with a technique called polymerase chain reaction, or P.C.R. But in a clinical study of nearly 200 people, Ellume’s product was able to detect 95 percent of the coronavirus infections found by P.C.R., regardless of whether the infected people felt sick. It also correctly identified 97 percent of the people who received negative laboratory test results.

Related article:  When consumer genetic tests disagree on critical mutations
Follow the latest news and policy debates on agricultural biotech and biomedicine? Subscribe to our newsletter.

Ellume, which was awarded a $30 million grant from the National Institutes of Health, said it planned to manufacture and deliver about 20 million home coronavirus tests to the United States within the first half of 2021. Each kit, which tests a single swab sample, is expected to cost about $30 or less.

ADVERTISEMENT

Read the original post

Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Deaths from COVID-19 are far higher than reported estimates

Infographic: Deaths from COVID-19 are far higher than reported estimates

More than 2.8 million people have lost their lives due to the pandemic, according to a Wall Street Journal analysis ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend